what is INVOKANA®?

INVOKANA® is Proven To Significantly Lower A1C Levels in Adults

INVOKANA® is proven to lower blood sugar (A1C)

Used along with diet and exercise, INVOKANA® is the first in the newest class of diabetes medicines (SGLT2 inhibitors) that’s proven to significantly lower A1C in adults living with type 2 diabetes.

INVOKANA® is a Once-Daily Pill For Type 2 Diabetes

INVOKANA® is a once-daily pill that works around the clock

INVOKANA® is Proven To Show Greater A1C Reductions than JANUVIA®

the 300-mg dose ofINVOKANA® is proven to show greater A1C reductions than Januvia® (sitagliptin)

Januvia® is a registered trademark of Merck Sharp & Dohme Corp.

INVOKANA® Can Help Contribute To Weight Loss in Patients

INVOKANA® is not for weight loss, but may help you lose weight—on average 3%

Results may vary by dose and
 when used with certain other diabetes medications.

INVOKANA® May Lower Systolic Blood Pressure in Adults

although it’s not a blood pressure medicine, you may see lower systolic blood pressure with INVOKANA®

Results may vary by dose and
 when used with certain other diabetes medications.

INVOKANA® Helped People Reach an A1C Goal of <7%

in most clinical trials, the majority of people taking INVOKANA® reached an A1C goal of less than 7%

As recommended by the American Diabetes Association.

Common Side Effects of INVOKANA®

the most common side effects of INVOKANA® include genital yeast infections, urinary tract infections, and changes in urination

watch our commercial

Talk to your doctor about whether INVOKANA® may be right for you. Not sure what to ask? Review the topics in our downloadable doctor discussion guide before your next check-in.

now that you know the facts, see if you can save with cost support from Janssen CarePath:

$0

co-pay every month*

sign up

*For most privately insured patients. Restrictions apply.